Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer
Carregando...
Citações na Scopus
46
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
IVYSPRING INT PUBL
Citação
JOURNAL OF CANCER, v.6, n.3, p.292-301, 2015
Resumo
The search for biomarkers to characterize prostate cancer aggressiveness has been the objective for the majority of researchers involved with the most prevalent tumor in men. MiRNAs are important for the control of many cellular functions and their deregulation is involved with tumor development and progression. To find miRNAs differentially expressed in prostate cancer and their relation to prognostic factors and biochemical recurrence we studied 53 surgical specimens from men who underwent radical prostatectomy, through a microarray analysis using the microarray platform (GeneChip (R) miRNA Array - Affymetrix) with more than 46,000 probes and 847 mature human miRNAs and transcripts. We defined different as an expression level greater or less than 1.1 with p<0.05. The validation study using qRT-PCR had confirmed miR21 as overexpressed in tumor that have recurred with a risk of 2.5. Transfection of miR-21 using lipid based assay in DU145 cell line, showed decrease in expression of RECK resulting in increase in expression of MMP9. Invasion assay with Matrigel showed increase in tumor cell invasion after miR-21 transfection. We conclude that miR-21 overexpression is related to increased biochemical recurrence after surgical treatment of prostate cancer. And the negative control of RECK results in overexpression of MMP9 promotes increasing tumor cell invasion supporting miR-21 as an oncomiR related to aggressiveness in prostate cancer.
Palavras-chave
Prostate cancer, Micro RNA, Microarray, Biochemical recurrence, Prognosis, miR-21, Cell invasion, RECK, DU145
Referências
- Algarra R, 2014, ACTAS UROLOGICAS ESP
- Chen Y, 2012, ANTICANCER RES, V32, P2991
- Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
- Epstein JI, 2012, EUR UROL, V61, P1019, DOI 10.1016/j.eururo.2012.01.050
- Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354
- Haffner MC, 2014, J CLIN ONCOLOGY OFFI
- Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
- Kattan MW, 1999, J CLIN ONCOL, V17, P1499
- Kollmeier Marisa A, 2012, Crit Rev Oncol Hematol, V84 Suppl 1, pe6, DOI 10.1016/j.critrevonc.2012.12.002
- Leite KRM, 2011, J UROLOGY, V185, P1118, DOI 10.1016/j.juro.2010.10.035
- Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
- Lexander H, 2005, PROTEOMICS, V5, P2570, DOI 10.1002/pmic.200401170
- Li T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082
- Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
- Lucca I, 2014, UROLOGIC ONCOLOGY
- Maugeri-Sacca M, 2012, CANCER J, V18, P253, DOI 10.1097/PPO.0b013e318258b5b6
- Moreira Leite Katia Ramos, 2009, Int J Radiat Oncol Biol Phys, V73, P353, DOI 10.1016/j.ijrobp.2008.04.039
- Nair VS, 2012, J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027
- Osman A, 2012, CLIN LAB, V58, P393
- Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809
- Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
- Reis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-14
- Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448
- Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
- Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
- Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
- Watahiki A, 2013, INT J MOL SCI, V14, P7757, DOI 10.3390/ijms14047757
- Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
- Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246
- Zhou L, 2013, INT J ONCOL, V43, P661, DOI 10.3892/ijo.2013.1965
- Zhu Q, 2012, ONCOL REP, V27, P1660, DOI 10.3892/or.2012.1682